x

  • Next Post
  • Previous Post

x

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
cache
Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009)
Read More
Anupam Dalal, MD

Comments

Comments are closed.

  • Next Post
  • Previous Post